PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
John M. Pagel, MD, PhD / Ian W. Flinn, MD, Ph - DConversations on the New Wave of Innovative Therapy in Follicular Lymphoma: Implications for Personalized Medicine
Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.
Jay H. Shubrook, DO, FAAFP, FACOFP - Partnering With Peers and Patients: Achieving T2DM Treatment Goals With GLP-1 RA Therapy
Go online to PeerView.com/PVT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in type 2 diabetes (T2DM) management discusses how to individualize treatment with GLP-1 RAs to improve outcomes for patients. Upon completion of this activity, participants should be better able to: Apply evidence-based treatment recommendations for GLP-1 RAs based on clinical trial results evaluating glycemic and extra-glycemic (eg, cardiovascular risk reduction, weight education) outcomes in patients with T2DM, Identify potential barriers to use (ie, mode of administration, adverse events) for current and emerging GLP-1 RAs, Engage in patient-centered discussions about the benefits and risks of using GLP-1 RAs to personalize management of T2DM.
Alexander (Ander) Cohen, MB BS (Hons), MSc, MD, FRACP, FESC - New Insights: How Does Real-World Evidence Influence VTE Management? A Visual Exploration of Real-World Studies of DOACs
Go online to PeerView.com/URQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a vascular medicine expert discusses real-world evidence (RWE) for treating patients with or at risk for venous thromboembolism (VTE) with direct oral anticoagulants (DOACs). Upon completion of this activity, participants will be able to: Explain the role of RWE and the impact it may have on improving care and outcomes in patients with VTE, Assess the quality and validity of the evidence collected as part of real-world studies comparing the DOACs with warfarin in patients with VTE (eg, efficacy, safety, cost-effectiveness, quality of life), Incorporate RWE into clinical decision-making for patients with VTE to design individualized treatment plans, especially for patients who may not be well represented in randomized clinical trials.
Edward J. Fox, MD, PhD - A Visual Guide to B-Cell Therapies in Relapsing MS: Clarifying the Options in an Expanding Treatment Landscape
Go online to PeerView.com/ZVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in multiple sclerosis discusses the role of B cells in MS pathogenesis and the use of anti-CD20 monoclonal antibodies in the management of relapsing forms of MS. Upon completion of this activity, participants should be better able to: Describe the role of B cells in the pathogenesis of relapsing multiple sclerosis (MS), Assess the mechanisms of action, safety, and efficacy of anti-CD20 monoclonal antibodies in the treatment of relapsing forms of MS, Apply best practices and clinical evidence when using B-cell–depleting therapies to optimize outcomes for patients with relapsing MS.
Marwan Sabbagh, MD, FAAN, CCRI - Expert Perspectives on the Early Diagnosis of Alzheimer’s Disease and the Promise of Novel Therapies on the Horizon
Go online to PeerView.com/FMQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people older than 65 years and increasing in global prevalence as the world’s population ages. Given the heavy economic and societal burdens of AD, major emphasis has been placed on finding disease-modifying therapies that can successfully delay or prevent the progression of AD. Although several hypotheses have been proposed regarding the causes of AD, the amyloid cascade hypothesis and the tau propagation hypothesis have gained the most support, and there are many novel agents under investigation for the treatment of AD that target Aβ or tau in a variety of ways. Recent advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. A multidisciplinary panel of AD experts provides an engaging discussion on the early recognition and diagnosis of AD, current and emerging treatment options and biomarkers, and optimal multidisciplinary management of patients with AD. They also explore ways in which different members of the multidisciplinary team can help to accommodate the influx of new treatable patients that will flood the healthcare system once a disease-modifying therapy is approved for AD. Upon completion of this activity, participants will be able to: Describe the rationale for screening for mild cognitive impairment (MCI) to identify patients at risk for AD early in the disease course, Apply validated neuroimaging techniques and biomarkers to make etiologically based diagnoses of AD, Assess key data sets on the efficacy, safety, and tolerability of available and emerging therapies for the treatment of AD, Employ a multidisciplinary team-based approach to manage the influx of patients that will need to be screened, diagnosed, and treated once a disease-modifying therapy is approved in AD.
Kristina M. Deligiannidis, MD - Test Your Knowledge: The Evidence for GABA-Modulating Neuroactive Steroids as a New Class of Rapid-Acting Antidepressants
Go online to PeerView.com/SZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in psychiatry discusses the use of GABA-modulating neuroactive steroids as rapid-acting antidepressants. Upon completion of this activity, participants should be better able to: Discuss the role of GABAergic dysfunction in PPD and MDD and the rationale for therapeutic targeting of GABA-A receptors with neuroactive steroids; Review the current treatment landscape and unmet needs of patients with MDD; Identify key barriers to the diagnosis and management of PPD; Apply recent evidence on the efficacy and safety of approved and emerging neuroactive steroids to the management of patients with PPD and MDD.